9 completed, 2 terminated, 1 not yet recruiting, 1 unknown. 8 Phase 2, 2 Not applicable, 2 Phase 3, 1 Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 6, Terminated 2 |
| Not applicable | 2 | Not yet recruiting 1, Unknown 1 |
| Phase 3 | 2 | Completed 2 |
| Phase 1 | 1 | Completed 1 |
| Phase 4 | 1 | Completed 1 |
Follow Epilepsy, Reflex: new trials by email Literature Review of Epilepsy, Reflex trials Research Report on Epilepsy, Reflex
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Epileptiform Potential of Fully Immersive Virtual Reality Virtual Reality Headset, display off, Virtual Reality Headset, Display only, Virtual Reality Headset, Display and Hand Control - Epilepsy, Seizure | Not applicable | Not yet recruiting | Dartmouth-Hitchcock Medical Center | 40 | 2026-12-01 | 2026-08-27 |
| A Double Blind, Randomized, Cross-over Study Examining the Suppression of the Photoparoxysmal EEG Response With NPT 2042 NPT 2042 - Photosensitive Epilepsy, Epilepsy | Phase 1 | Completed | NeuroPro Therapeutics, Inc. | 5 | 2024-08-21 | 2025-07-16 |
| Efficacy of Lenses in Abolishing Photoparoxysmal Responses Z1 lens, Experimental Lens 1, Experimental Lens 2 - Reflex Epilepsy, Photosensitive, Eyeglasses | Not applicable | Unknown | Aston University | 28 | 2021-02-20 | 2024-06-05 |
| Treatment of Sunflower Syndrome With ZX008 (Fenfluramine Hydrochloride) in Children and Young Adults (Ages 4-25). Fenfluramine Hydrochloride - Photosensitive Epilepsy | Phase 3 | Completed | Elizabeth Anne Thiele | 20 | 2019-05-31 | 2024-11-06 |
| A Study to Evaluate the Pharmacodynamic Activity of E2082 in Adult Participants With Photosensitive Epilepsy Placebo, E2082 - Photosensitive Epilepsy | Phase 2 | Terminated | Eisai Inc. | 8 | 2018-10-31 | 2020-09-28 |
| A Study to Evaluate the Pharmacodynamic Activity of E2730 in Adult Participants With Photosensitive Epilepsy Placebo, E2730 - Photosensitive Epilepsy | Phase 2 | Terminated | Eisai Inc. | 6 | 2018-07-27 | 2022-05-04 |
| Does BRV Have Faster Onset Time & Greater Effect Than LEV in Epilepsy Pts Using PPR Pharmacodynamic Efficacy Endpoint BRV vs LEV in randomized double blinded, crossover fashion - Photosensitive Epilepsy | Phase 2 / Phase 3 | Completed | Rosenfeld, William E., M.D. | 16 | 2018-06-01 | 2019-03-26 |
| A Study to Evaluate the Effect of ACT-709478 in Photosensitive Epilepsy Patients ACT-709478 for oral use, Placebo - Photosensitive Epilepsy | Phase 2 | Completed | Idorsia Pharmaceuticals Ltd. | 5 | 2017-10-06 | 2018-08-31 |
| PF-06372865 in Subjects With Photosensitive Epilepsy PF-06372865, Placebo, Lorazepam - Reflex Epilepsy, Photosensitive | Phase 2 | Completed | Pfizer | 7 | 2015-12-16 | 2018-03-14 |
| Photosensitivity Proof of Concept Trial carbamazepine 400mg, levetiracetam 1000mg - Photosensitive Epilepsy | Phase 2 | Completed | The Epilepsy Study Consortium | 6 | 2009-05-01 | 2012-03-05 |
| Effect of BGG492 on EEG in Patients With Photosensitive Epilepsy BGG492, Placebo - Photosensitive Epilepsy | Phase 2 | Completed | Novartis Pharmaceuticals | 13 | 2008-10-01 | 2016-09-23 |
| Effect of Valproic Acid Concentration on Photic Response Valproic Acid, Placebo - Photosensitive Epilepsy | Phase 4 | Completed | Vanderbilt University Medical Center | 13 | 2007-12-01 | 2017-06-14 |
| A Study of the Effects of JNJ-26489112 on the Photic Induced Paroxysmal Electroencephalogram (EEG) Response in Patients With Photosensitive Epilepsy JNJ-26489112, Placebo - Photosensitive Epilepsy | Phase 2 | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 12 | 2007-10-01 | 2012-04-05 |
Epilepsy (9) · Seizures (4) · Photosensitivity Disorders (2) · Erythema (1)
Brain Diseases (13) · Central Nervous System Diseases (13) · Nervous System Diseases (13) · Pathological Conditions, Signs and Symptoms (5) · Signs and Symptoms (5) · Epilepsy (4) · Neurologic Manifestations (4) · Skin Diseases (2) · Skin and Connective Tissue Diseases (2) · Skin Manifestations (1)
ACT-709478 (1) · Carbamazepine (1) · Fenfluramine (1) · Glucose (1) · Levetiracetam (1) · Lorazepam (1) · N-((6-chloro-2,3-dihydrobenzo(1,4)dioxin-2-yl)methyl)sulfamide (1) · PF-06372865 (1) · Saline Solution (1) · Valproic Acid (1) · Water (1) · selurampanel (1)
Eisai Inc. (2) · Aston University (1) · Dartmouth-Hitchcock Medical Center (1) · Elizabeth Anne Thiele (1) · Idorsia Pharmaceuticals Ltd. (1) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (1) · NeuroPro Therapeutics, Inc. (1) · Novartis Pharmaceuticals (1) · Pfizer (1) · Rosenfeld, William E., M.D. (1) · The Epilepsy Study Consortium (1) · Vanderbilt University Medical Center (1)
United States (9) · Germany (2) · France (1) · United Kingdom (1)
Ana Checa-Ros, MD, PhD (1) · Bassel Abou-Khalil, MD (1) · Bryony Carr, BSc (1) · Dorothee Kasteleijn-Nolst Trenite, MD, PhD (1) · Elizabeth Thiele, M.D., Ph.D. (1) · Jacqueline French, M.D. (1) · Jared E Quast, MD (1) · Sukhvir Wright, MD, PhD (1) · William E Rosenfeld, M.D. (1) · William Rosenfeld, MD (1)